FirstWord: Market Research Reports

... been tracking developments in the IPF market via a number of previous Physician View polls, focusing on the respective clinical profiles of Esbriet and Ofev ... pulmonologists based in the US and EU5 markets to provide their initial assessment of these two breakthrough drugs for IPF. Specifically we are asking ...

... the PCSK9 inhibitor class by recommending approval of Amgen's Repatha. The EMA has recommended approval of a broad label for Repatha in Europe, which includes those patients with ... or whom are intolerant to statins. Furthermore, Phase III data for Repatha has demonstrated LDL-C reductions of 46 percent to 64 percent from baseline at week ...

... -horse race among anti-CGRP mAbs for migraine.) Patients, physicians, payers and investors will be watching the progress being made with anti-CGRP mAbs closely as there ... for several anti-CGRP mAbs showed roughly a 1-day reduction in mean migraine days per month and 10% to 25% improvement in 50%-responder rates. If anti-CGRP mAbs are eventually approved ...

... access in critical emerging markets? With 12 in-depth case studies, Market Access Excellence for Emerging Markets analyses the pricing and market access issues you must understand now in critical, high-growth markets ... . FirstWord’s Market Access Excellence for Emerging Markets report summarises them, analyses them and prepares you to meet them. Key Benefitss Know which types of markets offer ...

Could your Medical Affairs team be better integrated for more effective cross-functional working that drives performance improvement? Building Strong Cross-functional Medical Affairs Teams examines how numerous pharma companies are working to leverage the potential of Medical Affairs in today ...

... personalised medicine and on the key challenges and opportunities in relation to implementation from treating oncologists. Personalised Medicines in Oncology: Assessing ...

... value and benefits of personalised medicine and on the key challenges and opportunities in relation to implementation from treating oncologists. Personalised Medicines in Oncology: Assessing Key Drivers and Challenges ... to development, access and implementation of personalised healthcare strategies. This survey provides US physician insights into personalised medicine within the oncology setting. By understanding what oncologists ...

... generic Copaxone may cause some healthcare providers in the US to promote injectable therapies over more expensive oral alternatives. This week's FirstWord Physician Views poll will ask US-based neurologists: What percentage of Copaxone patients they anticipate switching to a three-times ...

... status – will be presented at next year's ASCO meeting. To gain better physician insight on the potential future role of these two therapies, FirstWord ... ahead of current EGFR therapies such as Tarceva based on current data? What progression-free survival (PFS) benefit CO-1686 would have to demonstrate ...

... the best results. The bottom line here is that cancer immunotherapies will revolutionise cancer treatment and the fortunes of the companies who bring ... -Sarcoma Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA Paolo A. Ascierto, MD, Cancer Immunotherapy and Innovative Therapy Unit Istituto Nazionale ...

... status as a seemingly best-in-class integrase inhibitor, there is a chance that physicians could use dolutegravir primarily in Isentress failure patients (similarly as to how ... . To help gauge a more accurate view on how dolutegravir may shape the HIV market, this week's Physician Views poll will ask US-based infectious ...

... product to Lantus now known as Toujeo. See Physician Views Poll Results – Usage of Sanofi's U300 will not ... this point. In the oral diabetes market, there are two key trends to watch. In the GLP ... , FirstWord is polling US and EU5-based endocrinologists on five key questions ahead of the ADA meeting, Specifically ...

... and value of these teams. FirstWord's latest Physician Views poll seeks to gain some insight into how neurologists value the role that medical affairs personnel in the multiple sclerosis market play. Specifically we asked US and EU5-based doctors: How ...

... suggest could gain an increased share of the market should physicians shy away from Januvia, Onglyza and/or Nesina. To gain better understanding about ... of heart failure to labels for Onglyza and Nesina. With data from a cardiovascular (CV) outcomes trial of Januvia still to come (expected in June), what impact ...

... imperative to engage? Expanded Access Programs: Opportunities and Challenges for Pharma is a detailed report for industry management who must assess, approve or manage expanded access requests and ... and “real-world” research benefits of engaging in expanded access programmes Assess whether running your own expanded access programmes or engaging a service company is the route ...

What market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to availability to reimbursement factors, FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (EU5) provides insights that can help develop, shape and refine your brand strategies. Also Available is FirstView Barriers – An Analysis ...

What environmental market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to availability to reimbursement factors, FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (US) provides insights that can help develop, shape and refine your brand strategies. Also Available is FirstView Barriers – An Analysis of Market Barriers ...

Intarcia has previously suggested that it is the highest-valued privately owned ... ITCA 650 signed with Servier last year, through which Intarcia received a $171 million upfront payment, with a further $880 million ... that the mini-pump is not viewed by everyone as only having niche potential; as another KOL noted, many physicians in the field are likely ...

... 's Eylea). Converting any clinical advantage to the commercial setting may prove challenging, however, ... injection for Eylea. To better ascertain the impact of the Protocol T study results on uptake of Eylea, ... treatment of DME? In the first-line setting, what level of overall switching (or alternative new start ...

... physician sentiment to the CMS guidance. In our first poll, focused on Part B reimbursement, we are asking oncologists… How effective they expect the CMS reimbursement guidance to be in incentivising physicians ... of 'de-facto' interchangeability via CMS guidance Their view on interchangeability status for ...

... challenge of patient-centricity. Based on expert interviews, Harnessing the Power of Patient Support Programmes: pharma, patient and payer perspectivesuncovers key trends in patient relationship programs from patient, payer ... open arms. Insightful, wide ranging and compelling, Harnessing the Power of Patient Support Programmes: pharma, patient and payer perspectives offers new insights from ...

... of uptake, particularly as many KOLs expected Pfizer's drug to be priced lower. What does the performance and positioning of Xeljanz mean for other ... do you think will be necessary to drive adoption of baricitinib in favour of Xeljanz? What impact do you think availability of a cheaper, once-daily oral treatment ...

... modern pharma sales representative and what skills, knowledge, tools, training and incentives will make them really effective? Trends and Innovations in Sales Force Effectiveness is an important report for anyone looking to optimise their field sales force performance. This reports offers critical insights for sales and ...

... Esperion Therapeutics release promising Phase IIb data for its oral hypercholesterolaemia treatment ETC-1002. When added to stable statin therapy, a 180mg dose of ETC-1002 ... . Esperion CEO Tim Mayleben was in a bullish frame of mind as data for ETC-1002 broke last week, proclaiming the drug to represent a "patient friendly, physician ...

... safety issues first emerged? To gain better understanding about the views of doctors on the potential of gene therapy, FirstWord PLUS is polling US- and ... launched in Germany at a price of more than 1 million euros ($1.1 million). How concerned are you that gene therapies like this may prove cost ...

... data from AstraZeneca's PEGASUS-TIMI 54 study this weekend, their remains mixed views as to whether trial results will ... the PEGASUS study - noted that Plavix use in this setting is evidence that physicians ... do they think the PEGASUS data are? Whether they think the PEGASUS data will have an indirectly positive ...

... for. FirstWord polled US-based oncologists on this issue, among others, following the ODAC meeting in January (see Physician Views Poll Results: Positive FDA sentiment for biosimilar Neupogen shared by oncologists). While Zarxio is a trailblazer in the ...

... What’s more, Amgen will soon be looking at the possibility of facing additional competition from several oral proteasome inhibitors, which will ... . Porges is taking more optimistic view of Amgen's prospects and thinks Kyprolis ... much of an impact the ENDEAVOR results are likely to have with physicians, and whether ...

... characteristics for an ideal NASH therapy, as based on KOL feedback. This Physician Views poll uses that summary as inspiration and asks US and EU5 ...

... of nonalcoholic steatohepatitis (NASH) as a number of new therapies compete to become the first approved treatment for a disease that has high unmet clinical need. Nonalcoholic Steatohepatitis: KOL Insight reveals the critical views of US and European KOLs whose insights hold key lessons for pharma. Gain insights on products in the ...

... , risk-averse marketplace. Are you up to speed on all that a risk sharing agreement might do for your product or organization? Payer Perspectives on Risk Sharing offers expert insights on how risk sharing agreements can be a win-win for both pharmaceutical companies and payers in helping to build ...

FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (US) provides cutting edge, advanced and proprietary analytics ... the major markets of Europe – France, Germany, Italy, Spain, the UK prescribing to their MS patients? What is the top market barrier that forces a physician ...

FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (EU5) provides cutting edge, advanced and proprietary ... your brand is getting share from. The proprietary barrier instrument utilizes statistical analysis and advanced calculation to provide you with this precise ...

... do so many patients fail to adhere to their treatment programme? Trends and Innovations in Patient Adherenceis a thought-provoking and comprehensive report for everyone involved in ensuring patients comply ... Chief pharmacist, Spain Anonymous German KOL Patient Opinion Leaders Director, European Patients’ Academy on Therapeutic Innovation (EUPATI) Board member of the European Parkinson ...

... date, has vindicated the company's bullish stance on delivering the drug to market (ViewPoints: Pfizer sets out – earlier than expected – to show value ... evenly as to whether they thought Phase II results were sufficient to support regulatory clearance. A key question is whether this reticence will curb uptake ...

... include likely broad tier-3 formulary status at launch and the view among some analysts that endocrinologists will not proactively prescribe ... are discouraged to initiate insulin therapy due to injectable administration, while physician feedback sourced by FirstWord indicates that patients with needle phobia ...

... of the SGLT-2 class is likely to have reinforced this view. Reflecting an initially cautious view among analysts towards the SGLT-2 inhibitor class, consensus ... and what impact will the combination have on both the SGLT-2 and DPP-4 classes? To better understand we are polling US-based endocrinologists, asking ...

... has been in the US where both Ofev and Esbriet were approved in the fourth quarter of 2014 (Esbriet was approved in Europe during 2011, but InterMune was required to carry out additional Phase III studies to secure US clearance). See Physician Views ...

... , Spain and Italy, Medical Affairs Reputations (EU5): Biosimilar mAbs in Inflammatory Disorders offers insights on how Medical Affairs teams from companies developing and marketing biosimilar anti-TNF monoclonal ... , Spain, the UK; EU5 – biosimilar mAb developers and companies marketing branded mAbs require solid evidence upon which to base medical affairs’ strategy for their ...

... ? Renal Cell Carcinoma: KOL Insight offers opinions of 12 leading US and European KOLs that present business-critical insights for branded pharma and the drug discovery community. Gain insights ... 2 anonymous German KOLs Report Features Insightful drug and development analysis with “real world” opinions of leading US and European KOLs not available elsewhere ...

... The Rise of Wearable Healthcare Technology: Opportunities and Challenges for Pharma, FirstWord examines an emerging ... line between consumer and healthcare wearables is increasingly blurred—and how pharma can be part of a future in which wearing healthcare technology is the new normal ...

Trends and Innovations in Lifecycle Management (LCM) presents business-critical insights for strategic planners ... and anticipates, rather than reacts to, changes in the market. Trends and Innovations in Lifecycle Management offers unique expert insights into how you can ...

... versions of more complex pharmaceuticals – such as infliximab – raise key questions of physician sentiment, which will play a key role in shaping adoption and ...

... move, AbbVie agreed last month to provide its newly approved hepatitis C drug Viekira Pak to Express Scripts at an undisclosed discount in exchange for ... formulary exclusions) are viewed by the doctors, who will play a critical role as all-important prescribers of the medicines. Physician surveys and recently ...

... profile, at least initially. In the psoriasis setting (the IL-17A inhibitors are being studied across additional indications), the next 12 months could ... class as a whole. In response to EU approval, we are polling EU5 and US-based dermatologists with the following questions… How aware are you of secukinumab? How impressive ...

... expected. The overwhelmingly positive nature of the AdCom and the FDA's stance towards Zarxio are, nevertheless, highly encouraging. As is the ... PIONEER study). A critical factor in defining the success of biosimilars will be physician sentiment towards these products. Furthermore, this dynamic looks ...

... , with $47.3 billion, healthcare funding in 2014 dominated the technology space. In Google's Ambitions in Health, FirstWord maps the journey of one of the leading technology companies ... insights into Apple’s ambitions in the space Assessments of Google’s European and US investments and ventures Expert insight into DIY Health and its future ...

FirstWord’s Trends and Innovations in Drug Pricing report dissects international trends and examines how long-standing dynamics in competitive pricing and ... research and expert interviews, Trends and Innovations in Drug Pricing is an open window to the future of drug pricing. Worldwide, the trend towards payers determining price has ...

... be crucial in driving uptake. For example, there remains uncertainty as to whether AbbVie will ... is focused on whether the FDA takes the view that a minimum 95 percent sustained virological response ... -experienced and cirrhotic patients, and whether physicians also use ribavirin in treatment-naive genotype ...

... and value of these teams. FirstWord's latest Physician Views poll seeks to gain some insight into how endocrinologists value the role that medical affairs ... asking US and EU5-based physicians: How important they view medical affairs teams in enabling effective communication between physicians and pharmaceutical companies? Which activities ...